Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Journal for ImmunoTherapy of Cancer

Francesco M Marincola¹  Samir N Khleif⁵  Bernard A Fox³  Mary L Disis²  Lisa H Butterfield⁴ 

[1] Sidra Medical and Research Center, Doha, Qatar;University of Washington, Seattle, WA, USA;Oregon Health and Science University, Portland, OR, USA;University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh 15213, PA, USA;GRU Cancer Center, Georgia Regents University, Augusta, GA, USA

关键词: Clinical trial;    Immune monitoring;    Taskforce;    Biomarkers;    Immunotherapy;   

Others  :  1144129
DOI  :  10.1186/s40425-015-0052-6

 received in 2015-02-18, accepted in 2015-02-19,  发布年份 2015

【 摘 要 】

The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

【 授权许可】

   
2015 Butterfield et al; licensee BioMed Central.

【 参考文献 】

• [1]Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA: Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011, 9:214. BioMed Central Full Text
• [2]Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138.
• [3]Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, et al.: Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005, 28:79-119.
• [4]Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM: Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010, 8:130. BioMed Central Full Text
• [5]Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, et al.: A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”. J Transl Med 2008, 6:81. BioMed Central Full Text
• [6]Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, et al.: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011, 17:3064-3076.
• [7]Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, et al.: SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011, 9:155. BioMed Central Full Text
• [8]Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al.: The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1. BioMed Central Full Text
• [9]Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J: Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med 2012, 10:70. BioMed Central Full Text
• [10]Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al.: Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205. BioMed Central Full Text
• [11]Sunay M, Marincola F, Khleif SN, Silverstein SC, Fox BA, Galon J, et al.: Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. J Immunother Cancer 2013, 1:9. BioMed Central Full Text
• [12]Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al.: Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014, 312:1744-1753.